Trade Deal Looking Worse For Pharma As More Details Emerge
This article was originally published in The Pink Sheet Daily
Executive Summary
Trans-Pacific Partnership excludes patent linkage, evergreening provisions that industry had sought in addition to 12 years for biologics data exclusivity, which got knocked back to eight years.
You may also be interested in...
US-Mexico-Canada Trade Agreement Sets 10-Year Floor For Biologics Market Exclusivity
USA's 12-year-plus scheme won't change, but Canada and Mexico must offer sponsors more than previously; biosimilar industry bemoans lack of incentives for competition. Trade pact also specifies damages award options and links regulatory review to patent disputes.
US-Mexico-Canada Trade Agreement Sets 10-Year Floor For Biologics Market Exclusivity
USA's 12-year-plus scheme won't change, but Canada and Mexico must offer sponsors more than previously; biosimilar industry bemoans lack of incentives for competition. Trade pact also specifies damages award options and links regulatory review to patent disputes.
US-Mexico Trade Agreement Elicits Another Battle Over Biologics Data Exclusivity
Agreement in principle between US and Mexico would establish 10 years of data protection for biologic drugs, which AAM opposes.